

Major Products

Innovative pharmaceuticals *Major products cited in the text

Brand Name (Generic Name)	Efficacy	Launched	Marketed countries and regions	Remarks
Enhertu® (trastuzumab deruxtecan)	Anti-cancer agent (HER2 directed antibody drug conjugate)	2020	Global	Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells.
Lixiana® (edoxaban)	Anticoagulant	2011	Global	Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.
Tarlige® (mirogabalin)	Pain treatment	2019	Japan	An $\alpha 2 \delta$ ligand. The pain therapy agent to reduce the neurotransmitter release from nerve terminals.
Venofer® (iron sucrose injection)	Iron deficiency anemia treatment	2000	America	Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients, etc.
Nilemdo®/ Nustendi® (bempedoic acid or combination tablet of bempedoic acid and ezetimibe)	Cholesterol-lowering treatment	2020	EU	Bempedoic acid is an oral treatment which lowers cholesterol. It inhibits ATP Citrate Lyase, an enzyme which is involved in the production of cholesterol in the liver. Bempedoic acid/ ezetimibe reduces absorption of dietary cholesterol in the gut; it is an oral treatment which combines two complementary ways of reducing blood cholesterol levels.



Enhertu



Lixiana

OTC drug



Lulu



Minon

Shareholders' Information


Common Stock (As of March 31, 2024)

Number of shares authorized	8,400,000,000
Number of shares issued	1,947,034,029 (including 29,531,339 treasury shares)
Number of shareholders	92,038

Major Shareholders (As of March 31, 2024)

Name	Number of Shares Held (Thousands of shares)	Ratio(%)
The Master Trust Bank of Japan, Ltd. (trust account)	320,049	16.69
Custody Bank of Japan, Ltd. (trust account)	163,473	8.53
JP MORGAN CHASE BANK 385632	117,255	6.11
Nippon Life Insurance Company	85,863	4.48
STATE STREET BANK AND TRUST COMPANY 505001	53,230	2.78
SSBTC CLIENT OMNIBUS ACCOUNT	52,935	2.76
STATE STREET BANK WEST CLIENT-TREATY 505234	36,407	1.90
GOVERNMENT OF NORWAY	29,150	1.52
JP MORGAN CHASE BANK 385781	26,213	1.37
Custody Bank of Japan, Ltd. as trustee for Mizuho Bank, Ltd. Retirement Benefit Trust Account re-entrusted by Mizuho Trust and Banking Co., Ltd.	25,014	1.30

Market Capitalization and Changes in Stock Price



*Stock prices and market capitalization are based on closing price at the end of month from March 2008 to August 2024. Stock price is post-share split base (Effective October 1, 2020, Daiichi Sankyo implemented a three-for-one share split of its ordinary shares). Market capitalization is calculated excluding treasury stocks.

Share Registrar

Mitsubishi UFJ Trust and Banking Corporation


Mailing address and telephone number

Mitsubishi UFJ Trust and Banking Corporation Corporate Agency Division

Shin-TOKYO Post Office post office box No.29, 137-8081, Japan

Tel: 0120-232-711 (toll free within Japan)

Distribution of Shareholders (As of March 31, 2024)



Trends in Total Shareholder Return

